Publications

  1. Khurana A, Jung-Beom D, He X, Kim SH, Busby RC, Lorenzon L, Villa M, Baldi A, Molina J, Goetz MP, Shridhar V. Matrix detachment and proteasomal inhibitors diminish Sulf-2 expression in breast cancer cell lines and mouse xenografts. Clin Exp Metastasis. 2013 Apr; 30(4):407-15. Epub 2013 Feb 15. 2304036
    View PubMed
  2. Dy GK, Mandrekar SJ, Nelson GD, Meyers JP, Adjei AA, Ross HJ, Ansari RH, Lyss AP, Stella PJ, Schild SE, Molina JR, Adjei AA. A randomized phase II study of gemcitabine and carboplatin with or without cediranib as first-line therapy in advanced non-small-cell lung cancer: North Central Cancer Treatment Group Study N0528. J Thorac Oncol. 2013 Jan; 8(1):79-88. 2289488
    View PubMed
  3. Velasco MJ, Molina J. Estrium Whey induced hepatitis in a patient with metastatic breast cancer: Case report. World J Hepatol. 2012 Dec 27; 4(12):399-401. 2299555
    View PubMed
  4. Schild SE, Foster NR, Meyers JP, Ross HJ, Stella PJ, Garces YI, Olivier KR, Molina JR, Past LR, Adjei AA, North Central Cancer Treatment Group. Prophylactic cranial irradiation in small-cell lung cancer: findings from a North Central Cancer Treatment Group Pooled Analysis. Ann Oncol. 2012 Nov; 23(11):2919-24. Epub 2012 Jul 10. 2290692
    View PubMed
  5. Bible KC, Suman VJ, Menefee ME, Smallridge RC, Molina JR, Maples WJ, Karlin NJ, Traynor AM, Kumar P, Goh BC, Lim WT, Bossou AR, Isham CR, Webster KP, Kukla AK, Bieber C, Burton JK, Harris P, Erlichman C, Mayo Phase 2 Consortium, Mayo Clinic Endocrine A multiinstitutional phase 2 trial of pazopanib monotherapy in advanced anaplastic thyroid cancer. J Clin Endocrinol Metab. 2012 Sep; 97(9):3179-84. Epub 2012 Jul 06. 2281124
    View PubMed
  6. Reungwetwattana T, Weroha SJ, Molina JR. Oncogenic pathways, molecularly targeted therapies, and highlighted clinical trials in non-small-cell lung cancer (NSCLC). Clin Lung Cancer. 2012 Jul; 13(4):252-66. Epub 2011 Dec 08. 2210852
    View PubMed
  7. Bible KC, Smallridge RC, Morris JC, Molina JR, Suman VJ, Copland JA, Rubin J, Menefee ME, Sideras K, Maples WJ, McIver B, Fatourechi V, Hay I, Foote RL, Garces YI, Kasperbauer JL, Thompson GB, Grant CS, Richards ML, Sebo T, Lloyd R, Eberhardt NL, Reddi Development of a multidisciplinary, multicampus subspecialty practice in endocrine cancers. Am J Manag Care. 2012 May; 18(5):e162-7. Epub 2012 May 01. 2246034
    View PubMed
  8. Reungwetwattana T, Molina JR, Mandrekar SJ, Allen-Ziegler K, Rowland KM, Reuter NF, Luyun RF, Dy GK, Marks RS, Schild SE, Jett JR, Adjei AA. Brief report: a phase II "window-of-opportunity" frontline study of the MTOR inhibitor, temsirolimus given as a single agent in patients with advanced NSCLC, an NCCTG study. J Thorac Oncol. 2012 May; 7(5):919-22. 2246523
    View PubMed
  9. Bible KC, Smallridge RC, Morris JC, Molina JR, Suman VJ, Copland JA, Rubin J, Menefee ME, Sideras K, Maples WJ, McIver B, Fatourechi V, Hay I, Foote RL, Garces YI, Kasperbauer JL, Thompson GB, Grant CS, Richards ML, Sebo T, Lloyd R, Eberhardt NL, Reddi HV Development of a multidisciplinary, multicampus subspecialty practice in endocrine cancers. J Oncol Pract. 2012 May; 8(3 Suppl):e1s-5s. 2268579
    View PubMed
  10. Yang P, Kulig K, Boland JM, Erickson-Johnson MR, Oliveira AM, Wampfler J, Jatoi A, Deschamps C, Marks R, Fortner C, Stoddard S, Nichols F, Molina J, Aubry MC, Tang H, Yi ES. Worse disease-free survival in never-smokers with ALK+ lung adenocarcinoma. J Thorac Oncol. 2012 Jan; 7(1):90-7. 2208572
    View PubMed
  11. Molina JR, Foster N, Reungwetwattana T, Nelson G, Grainger AV, Steen PD, Stella PJ, Marks RS, Wright J, Adjei AA. A phase II trial of the Src-kinase inhibitor saracatinib after 4 cycles of chemotherapy for patients with extensive stage small cell lung cancer: NCCTG trial N-0621. J Thor Oncol. 2012. 2140306
    View PubMed
  12. Pankratz VS, Sun Z, Aakre J, Li Y, Johnson C, Garces YI, Aubry MC, Molina JR, Wigle DA, Yang P. Systematic evaluation of genetic variants in three biological pathways on patient survival in low-stage non-small cell lung cancer. J Thorac Oncol. 2011 Sep; 6(9):1488-95. 2179333
    View PubMed
  13. Li Y, Sun Z, Cunningham JM, Aubry MC, Wampfler JA, Croghan GA, Johnson C, Wu D, Aakre JA, Molina J, Wang L, Pankratz VS, Yang P. Genetic variations in multiple drug action pathways and survival in advanced stage non-small cell lung cancer treated with chemotherapy. Clin Cancer Res. 2011 Jun 1; 17(11):3830-40. 2168509
    View PubMed
  14. Weiss GJ, Infante JR, Chiorean EG, Borad MJ, Bendell JC, Molina JR, Tibes R, Ramanathan RK, Lewandowski K, Jones SF, Lacouture ME, Langmuir VK, Lee H, Kroll S, Burris HA 3rd. Phase 1 study of the safety, tolerability, and pharmacokinetics of TH-302, a hypoxia-activated prodrug, in patients with advanced solid malignancies. Clin Cancer Res. 2011 May 1; 17(9):2997-3004. Epub 2011 Mar 17. 2161983
    View PubMed
  15. Foster NR, Qi Y, Shi Q, Krook JE, Kugler JW, Jett JR, Molina JR, Schild SE, Adjei AA, Mandrekar SJ. Tumor response and progression-free survival as potential surrogate endpoints for overall survival in extensive stage small-cell lung cancer: findings on the basis of North Central Cancer Treatment Group trials. Cancer. 2011 Mar 15; 117(6):1262-71. Epub 2010 Oct 19. 2121159
    View PubMed
  16. Midthun DE, Molina JR. Lung cancer: evolving concepts. Semin Respir Crit Care Med. 2011 Feb; 32(1):1-2. Epub 2011 Apr 15. 2160233
    View PubMed
  17. Reungwetwattana T, Eadens MJ, Molina JR. Chemotherapy for non-small-cell lung carcinoma: from a blanket approach to individual therapy. Semin Respir Crit Care Med. 2011 Feb; 32(1):78-93. Epub 2011 Apr 15. 2155406
    View PubMed
  18. Foote RL, Molina JR, Kasperbauer JL, Lloyd RV, McIver B, Morris JC, Grant CS, Thompson GB, Richards ML, Hay ID, Smallridge RC, Bible KC. Enhanced survival in locoregionally confined anaplastic thyroid carcinoma: a single-institution experience using aggressive multimodal therapy. Thyroid. 2011 Jan; 21(1):25-30. Epub 2010 Dec 16. 2135890
    View PubMed
  19. Reungwetwattana T, Jaramillo S, Molina JR. Current and emerging therapies in peripheral T-cell lymphoma: Focus on pralatrexate. Clinical Medicine Insights: Therapeutics. 2011; 3:125-35. 2173679
  20. Molina JR, Rowland KM, Foster NR, Dy GD, Aubry MC, Flynn PJ, Zon RT, Pajon ER, Wilbur DW, Kugler JW, Adjei AA. A Phase II Randomized Study of Pemtrexed With Sorafenib Versus Pemetrexed Alone as Second-Line Therapy in Patients With Advanced Non-Small Cell Lung Cancer. Cancer. 2011. 2212547
    View PubMed
  21. Schild SE, Foster NR, Meyers JP, Ross HJ, Stella PJ, Garces YI, Olivier KR, Molina JR, Past LR, Adjei AA. Prophylactic cranial irradiation (PCI) in small cell lung cancer (SCLC): findings from a north central cancer treatment group (NCCTG) meta-analysis. J Thoracic Oncol. Submitted 2011. 2212561
    View PubMed
  22. Dy GK, Hillman SL, Rowland KM Jr, Molina JR, Steen PD, Wender DB, Nair S, Mandrekar S, Schild SE, Adjei AA, North Central Cancer Treatment Group Study N0326. A front-line window of opportunity phase 2 study of sorafenib in patients with advanced nonsmall cell lung cancer: North Central Cancer Treatment Group Study N0326. Cancer. 2010 Dec 15; 116(24):5686-93. 2180631
    View PubMed
  23. Heist RS, Fain J, Chinnasami B, Khan W, Molina JR, Sequist LV, Temel JS, Fidias P, Brainerd V, Leopold L, Lynch TJ. Phase I/II study of AT-101 with topotecan in relapsed and refractory small cell lung cancer. J Thorac Oncol. 2010 Oct; 5(10):1637-43. 2118999
    View PubMed
  24. Bible KC, Suman VJ, Molina JR, Smallridge RC, Maples WJ, Menefee ME, Rubin J, Sideras K, Morris JC 3rd, McIver B, Burton JK, Webster KP, Bieber C, Traynor AM, Flynn PJ, Goh BC, Tang H, Ivy SP, Erlichman C, Endocrine Malignancies Disease Oriented Group, Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study. Lancet Oncol. 2010 Oct; 11(10):962-72. Epub 2010 Sep 17. 2213666
    View PubMed
  25. Adjei AA, Salavaggione OE, Mandrekar SJ, Dy GK, Ziegler KL, Endo C, Molina JR, Schild SE, Adjei AA. Correlation between polymorphisms of the reduced folate carrier gene (SLC19A1) and survival after pemetrexed-based therapy in non-small cell lung cancer: a North Central Cancer Treatment Group-based exploratory study. J Thorac Oncol. 2010 Sep; 5(9):1346-53. 2109188
    View PubMed
  26. Chee CE, Jett JR, Bernath AM Jr, Foster NR, Nelson GD, Molina J, Nikcevich DA, Steen PD, Flynn PJ, Rowland KM Jr. Phase 2 trial of pemetrexed disodium and carboplatin in previously untreated extensive-stage small cell lung cancer, N0423. Cancer. 2010 May 15; 116(10):2382-9. 1990487
    View PubMed
  27. Zhang J, Zhao D, Park HK, Wang H, Dyer RB, Liu W, Klee GG, McNiven MA, Tindall DJ, Molina JR, Fei P. FAVL elevation in human tumors disrupts Fanconi anemia pathway signaling and promotes genomic instability and tumor growth. J Clin Invest. 2010 May; 120(5):1524-34. Epub 2010 Apr 19. 1997831
    View PubMed
  28. Adjei AA, Mandrekar SJ, Dy GK, Molina JR, Adjei AA, Gandara DR, Ziegler KL, Stella PJ, Rowland KM Jr, Schild SE, Zinner RG. Phase II trial of pemetrexed plus bevacizumab for second-line therapy of patients with advanced non-small-cell lung cancer: NCCTG and SWOG study N0426. J Clin Oncol. 2010 Feb 1; 28(4):614-9. Epub 2009 Oct 19. 2101989
    View PubMed
  29. Beleford D, Liu Z, Rattan R, Quagliuolo L, Boccellino M, Baldi A, Maguire J, Staub J, Molina J, Shridhar V. Methylation induced gene silencing of HtrA3 in smoking-related lung cancer. Clin Cancer Res. 2010 Jan 15; 16(2):398-409. Epub 2010 Jan 12. 1980482
    View PubMed
  30. Dy G, Hillman S, Rowland K, Molina J, Steen P, Wender D, Nair S, Mandrekar S, Schild S, Adjei A. A Front-Line "Window of Opportunity" Phase II Study of Sorafenib in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) - A North Central Cancer Treatment Group Study N0326. Cancer. 2009. 2011039
    View PubMed
  31. Chien J, Narita K, Rattan R, Giri S, Shridhar R, Staub J, Beleford D, Lai J, Roberts LR, Molina J, Kaufmann SH, Prendergast GC, Shridhar V. A role for candidate tumor-suppressor gene TCEAL7 in the regulation of c-Myc activity, cyclin D1 levels and cellular transformation. Oncogene. 2008 Dec 11; 27(58):7223-34. Epub 2008 Sep 22. 1915634
    View PubMed
  32. Molina JR, Kaufmann SH, Reid JM, Rubin SD, Galvez-Peralta M, Friedman R, Flatten KS, Koch KM, Gilmer TM, Mullin RJ, Jewell RC, Felten SJ, Mandrekar S, Adjei AA, Erlichman C. Evaluation of lapatinib and topotecan combination therapy: tissue culture, murine xenograft, and phase I clinical trial data. Clin Cancer Res. 2008 Dec 1; 14(23):7900-8. 1884742
    View PubMed
  33. Ahmed AU, Schmidt RL, Park CH, Reed NR, Hesse SE, Thomas CF, Molina JR, Deschamps C, Yang P, Aubry MC, Tang AH. Effect of disrupting seven-in-absentia homolog 2 function on lung cancer cell growth. J Natl Cancer Inst. 2008 Nov 19; 100(22):1606-29. Epub 2008 Nov 11. 1915383
    View PubMed
  34. Macarenco RS, Uphoff TS, Gilmer HF, Jenkins RB, Thibodeau SN, Lewis JE, Molina JR, Yang P, Aubry MC. Salivary gland-type lung carcinomas: an EGFR immunohistochemical, molecular genetic, and mutational analysis study. Mod Pathol. 2008 Sep; 21(9):1168-75 Epub 2008 Jun 27. 1934854
    View PubMed
  35. Mateen FJ, Jatoi A, Lineberry TW, Aranguren D, Creagan ET, Croghan GA, Jett JR, Marks RS, Molina JR, Richardson RL. Do patients with schizophrenia receive state-of-the-art lung cancer therapy? A brief report. Psychooncology. 2008 Jul; 17(7):721-5. 1904645
    View PubMed
  36. Molina JR. Pralatrexate, a dihydrofolate reductase inhibitor for the potential treatment of several malignancies. IDrugs. 2008 Jul; 11(7):508-21. 1900779
    View PubMed
  37. Adjei AA, Cohen RB, Franklin W, Morris C, Wilson D, Molina JR, Hanson LJ, Gore L, Chow L, Leong S, Maloney L, Gordon G, Simmons H, Marlow A, Litwiler K, Brown S, Poch G, Kane K, Haney J, Eckhardt SG. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008 May 1; 26(13):2139-46. Epub 2008 Apr 07. 1904823
    View PubMed
  38. Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc. 2008 May; 83(5):584-94. 1885168
    View PubMed
  39. Diago T, Pulido JS, Molina JR, Collett LC, Link TP, Ryan EH Jr. Ranibizumab combined with low-dose sorafenib for exudative age-related macular degeneration. Mayo Clin Proc. 2008 Feb; 83(2):231-4. 1867766
    View PubMed
  40. Molina JR, Quevedo JF, Furth AF, Richardson RL, Zincke H, Burch PA. Predictors of survival from urachal cancer: a Mayo Clinic study of 49 cases. Cancer. 2007 Dec 1; 110(11):2434-40. 1858405
    View PubMed
  41. Aubry MC, Heinrich MC, Molina J, Lewis JE, Yang P, Cassivi SD, Corless CL. Primary adenoid cystic carcinoma of the lung: absence of KIT mutations. Cancer. 2007 Dec 1; 110(11):2507-10. 1858406
    View PubMed
  42. Molina JR, Aubry MC, Lewis JE, Wampfler JA, Williams BA, Midthun DE, Yang P, Cassivi SD. Primary salivary gland-type lung cancer: spectrum of clinical presentation, histopathologic and prognostic factors. Cancer. 2007 Nov 15; 110(10):2253-9. 1858407
    View PubMed
  43. Haluska P, Shaw HM, Batzel GN, Yin D, Molina JR, Molife LR, Yap TA, Roberts ML, Sharma A, Gualberto A, Adjei AA, de Bono JS. Phase I dose escalation study of the anti insulin-like growth factor-I receptor monoclonal antibody CP-751,871 in patients with refractory solid tumors. Clin Cancer Res. 2007 Oct 1; 13(19):5834-40. 2157507
    View PubMed
  44. Staub J, Chien J, Pan Y, Qian X, Narita K, Aletti G, Scheerer M, Roberts LR, Molina J, Shridhar V. Epigenetic silencing of HSulf-1 in ovarian cancer:implications in chemoresistance. Oncogene. 2007 Jul 26; 26(34):4969-78. Epub 2007 Feb 19. 1836892
    View PubMed
  45. Adjei AA, Molina JR, Mandrekar SJ, Marks R, Reid JR, Croghan G, Hanson LJ, Jett JR, Xia C, Lathia C, Simantov R. Phase I trial of sorafenib in combination with gefitinib in patients with refractory or recurrent non-small cell lung cancer. Clin Cancer Res. 2007 May 1; 13(9):2684-91. 1818776
    View PubMed
  46. Endo C, Sun Z, Molina JR, Attewell JR, Yang P. Evaluation of reference genes for normalization of quantitative real time PCR in non-small cell lung cancer. International Journal of Cancer Research. 2007; 3(1):1-12. 1975798
    View PubMed
  47. Molina JR, Adjei AA, Jett JR. Advances in chemotherapy of non-small cell lung cancer. Chest. 2006 Oct; 130(4):1211-9. 1789305
    View PubMed
  48. Molina JR, Jett JR, Foster N, Lair BS, Carroll TJ, Tazelaar HD, Hillman S, Mailliard JA, Bernath AM Jr, Nikcevich D. Phase II NCCTG trial of oral topotecan and paclitaxel with G-CSF (filgrastim) support in patients with previously untreated extensive-stage small cell lung cancer. Am J Clin Oncol. 2006 Jun; 29(3):246-51. 1765219
    View PubMed
  49. Molina JR, Nikcevich D, Hillman S, Geyer S, Drevyanko T, Jett J, Verdirame J, Tazelaar H, Rowland K, Wos E, Kutteh L, Nair S, Fitch T, Flynn P, Stella P, Adjei AA. A Phase II NCCTG study of irinotecan and docetaxel in previously treated patients with non-small cell lung cancer. Cancer Invest. 2006 Jun-Jul; 24(4):382-9. 1770009
    View PubMed
  50. Osborn NK, Zou H, Molina JR, Lesche R, Lewin J, Lofton-Day C, Klatt KK, Harrington JJ, Burgart LJ, Ahlquist DA. Aberrant methylation of the eyes absent 4 gene in ulcerative colitis-associated dysplasia. Clin Gastroenterol Hepatol. 2006 Feb; 4(2):212-8. 1750559
    View PubMed
  51. Molina JR, Adjei AA. The Ras/Raf/MAPK pathway. J Thorac Oncol. 2006 Jan; 1(1):7-9. 1772802
    View PubMed
  52. Ward IM, Difilippantonio S, Minn K, Mueller MD, Molina JR, Yu X, Frisk CS, Ried T, Nussenzweig A, Chen J. 53BP1 cooperates with p53 and functions as a haploinsufficient tumor suppressor in mice. Mol Cell Biol. 2005 Nov; 25(22):10079-86. 1733734
    View PubMed
  53. Molina JR, Reid JM, Erlichman C, Sloan JA, Furth A, Safgren SL, Lathia CD, Alberts SR. A phase I and pharmacokinetic study of the selective, non-peptidic inhibitor of matrix metalloproteinase BAY 12-9566 in combination with etoposide and carboplatin. Anticancer Drugs. 2005 Oct; 16(9):997-1002. 1732134
    View PubMed
  54. Zou H, Molina JR, Harrington JJ, Osborn NK, Klatt KK, Romero Y, Burgart LJ, Ahlquist DA. Aberrant methylation of secreted frizzled-related protein genes in esophageal adenocarcinoma and Barrett's esophagus. Int J Cancer. 2005 Sept 10; 116(4):584-91. 1721380
    View PubMed
  55. Giordano KF, Jatoi A, Adjei AA, Creagan ET, Croghan G, Frytak S, Jett JR, Marks R, Molina J, Okuno S, Richardson RL. Ramifications of severe organ dysfunction in newly diagnosed patients with small cell lung cancer: contemporary experience from a single institution. Lung Cancer. 2005 Aug; 49(2):209-15. 1729980
    View PubMed
  56. Zou HZ, Osborn NK, Harrington JJ, Klatt KK, Molina JR, Burgart LJ, Ahlquist DA. Frequent methylation of eyes absent 4 gene in Barrett's esophagus and esophageal adenocarcinoma. Cancer Epidemiol Biomarkers Prev. 2005 Apr; 14(4):830-4. 1708098
    View PubMed
  57. Fernandez-Zapico ME, Gonzalez-Paz NC, Weiss E, Savoy DN, Molina JR, Fonseca R, Smyrk TC, Chari ST, Urrutia R, Billadeau DD. Ectopic expression of VAV1 reveals an unexpected role in pancreatic cancer tumorigenesis. Cancer Cell. 2005 Jan; 7(1):39-49. 1680895
    View PubMed
  58. Molina JR, Barton DL, Loprinzi CL. Chemotherapy-induced ovarian failure: manifestations and management. Drug Saf. 2005; 28(5):401-16. 1718799
    View PubMed
  59. Sun Z, Yang P, Aubry MC, Kosari F, Endo C, Molina J, Vasmatzis G. Can gene expression profiling predict survival for patients with squamous cell carcinoma of the lung? Mol Cancer. 2004 Dec 03; 3(1):35. 1703738
    View PubMed
  60. Yang P, Sun Z, Aubry MC, Kosari F, Bamlet W, Endo C, Molina JR, Vasmatzis G. Study design considerations in clinical outcome research of lung cancer using microarray analysis. Lung Cancer. 2004 Nov; 46(2):215-26. 1669444
    View PubMed
  61. Visbal AL, Williams BA, Nichols FC III, Marks RS, Jett JR, Aubry MC, Edell ES, Wampfler JA, Molina JR, Yang P. Gender differences in non-small-cell lung cancer survival: an analysis of 4,618 patients diagnosed between 1997 and 2002. Ann Thorac Surg. 2004 Jul; 78(1):209-15. 1653021
    View PubMed
  62. Molina JR, Adjei AA. The role of Pemetrexed (Alimta , LY231514) in lung cancer therapy. Clin Lung Cancer. 2003 Jul; 5(1):21-7. 1644138
    View PubMed
  63. Dai Z, Wei-Guo Z, Morrison CD, Brena RM, Smiraglia DJ, Aparna R, Yue-Zhong W, Rush LJ, Ross P, Molina JR, Otterson GA, Plass C. A comprehensive search for DNA amplification in lung cancer identifies inhibitors of apoptosis cIAP1 and cIAP2 as candidate oncogenes. Hum Mol Genet. 2003; 12(7):791-801. 1748986
    View PubMed
  64. Boivin GP, Molina JR, Ormsby I, Stemmerman G, Doetschman T. Gastric lesions in TGFB-1 heterozygous mice. Lab Invest. 1996; 74:513-8. 1748982
    View PubMed